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Abstract Trastuzumab has conferred significant clinical
benefits in HER-2-positive breast carcinomas. HER-2 sta-
tus is determined by immunohistochemistry (IHC) and/or
fluorescence in situ hybridisation (FISH), but appropriate
assessment of HER2 status remains subject to considerable
debate. Data on the health economic impact of HER-2 test
strategies are limited. A life-long Markov state transition
model was used to assess costs and effectiveness of HER-2
assay strategies (based on IHC, FISH, both combined or
FISH confirmation of IHC2?) for a hypothetical cohort of
early breast cancer patients from the perspective of the
Swiss health system. We compared clinically relevant
strategies of predictive testing and subsequent trastuzumab
treatment of HER-2-positive patients only. FISH testing
was the most cost–effective strategy with an incremental
cost–effectiveness ratio of €12,245 per additional quality-
adjusted life-year (QALY) gained, compared to no trast-
uzumab treatment. The next best strategy was parallel IHC
and FISH, with costs of €400,154/QALY gained compared
to FISH alone. FISH as primary HER-2 testing modality
remained the preferred option in deterministic and proba-
bilistic sensitivity analysis. Predictive testing to identify
adjuvant breast cancer patients who benefit from trast-
uzumab treatment is a clinical and economic necessity. Our
model identifies FISH as the most cost–effective approach.
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Introduction
Human epidermal growth factor receptor 2 (HER-2/neu,
hereafter referred to as HER-2), is a transmembrane
receptor tyrosine kinase expressed in epithelial cells
including the breast. Approximately 20–25% of breast
cancers patients show HER-2 protein overexpression and/
or HER-2 oncogene amplification [1–4]. Both are markers
for aggressive disease [5, 6] and the molecular targets of
trastuzumab (Herceptin, Roche Pharma, Switzerland) and
lapatinib (GlaxoSmithKline, London, UK). Trastuzumab, a
humanized monoclonal antibody, is used successfully in
the therapy of HER-2-positive invasive breast carcinomas
[7–10]. In the adjuvant setting, it substantially reduces
recurrence rates and overall mortality in combination with
chemotherapy [11–14]. There is now consensus on a life-
prolonging effect in metastatic, early node-positive and
node-negative HER-2 positive invasive breast cancers.
Trastuzumab has also dramatically increased treatment
costs [15].
Gene amplification and protein overexpression can be
identified by immunohistochemistry (IHC) or fluorescence
in situ hybridisation (FISH), respectively [7]. Despite a
long history of predictive HER-2 testing in breast cancer
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patients, there is still no consensus on the most appropriate
testing approach. Selection criteria include accuracy,
reproducibility and precision but also cost [16]. Published
results comparing HER-2 status determined by FISH or
IHC in formalin fixed, paraffin embedded (FFPE) tissues
are contradictory. Standardization of IHC in FFPE tissue
samples is difficult due to pre-analytical problems and high
subjectivity in interpretation. Concordance rates range
between 80 and 90%, depending on the methodology,
instrumentation and experience of the laboratories carrying
out the tests [17]. This implies significant numbers of false
negative test results, which may have dramatic conse-
quences for the affected patients [18]. Current American
Society of Clinical Oncology and the College of American
Pathologists (ASCO-CAP) guidelines recommend the use
of IHC for initial evaluation of HER-2 status but initial use
of FISH is also discussed [19]. Arguments for FISH include
better reproducibility and accuracy, although FISH is more
expensive than IHC [20].
Expensive new cancer therapies are usually regarded as
appropriate if trial data show clinically relevant improve-
ments [21, 22]. Several publications have addressed the
cost–effectiveness of trastuzumab in HER-2-positive breast
cancer patients [23–25]. Markov models have been used to
evaluate the cost–effectiveness of HER-2 testing strategies
in the adjuvant and metastatic settings [26–28] but com-
prehensive cost–effectiveness analysis comparing alterna-
tive assay strategies are limited.
Using a life-long Markov state transition model, we
evaluated the health economic impact of trastuzumab
treatment of adjuvant breast cancer in Switzerland and the
influence of different HER-2-testing strategies (IHC, FISH,
both combined or FISH confirmation of IHC2? status)
[29]. The model can also be used for similar decision
problems arising with other predictive tests in pathology.
Methodology
Overview of breast cancer disease model
A Markov model with a cycle length of 1 year was used to
reproduce the disease process and economic consequences.
Economic endpoints were the costs associated with each
strategy. Effectiveness was assessed as quality-adjusted
life-years (QALYs). Incremental cost–effectiveness ratios
(ICERs) were planned to be calculated if applicable, i.e. in
non-dominant situations. The time horizon of the analysis
was life-long (50 years).
Costs were assessed from the perspective of the Swiss
health care system. Consequently, non-medical and indi-
rect costs were disregarded. Direct medical costs included
drug costs, costs for predictive testing (where applicable),
gynaecological examinations, diagnostic procedures and
hospitalization (Table 3). Costs and effects were dis-
counted at 3% [21]. Costs are shown in Euros (€). In March
2009, €1.00 equalled Swiss Francs (CHF) 1.50.
Patient populations studied
The model assessed a hypothetical cohort of female
breast cancer patients aged 50 years, of whom 20% were
HER-2-positive. The HER-2-positive patient population
was defined by the eligibility criteria of the HERA trial
[12]. In brief, patients had centrally validated HER-2-
positive early stage invasive breast cancer with either
node-positive or node-negative disease status (disease-free
status). They completed local regional therapy and at
least four courses of predefined standard adjuvant or
neoadjuvant chemotherapy. Eligibility criteria for disease-
free HER-2-negative patients were WHO performance
status 0–1 with a confirmed HER-2-negative status. They
had undergone breast surgery with axillary-node dissec-
tion or sentinel-node biopsy for invasive breast carcinoma
[11].
Strategies compared
We assessed the following testing strategies: IHC alone,
FISH alone, parallel IHC and FISH, sequential testing
with FISH confirmation of IHC2?. Patients with positive
IHC (2? or 3?) and/or positive FISH received adjuvant
trastuzumab treatment. Patients with no or a very low
HER-2 expression levels (IHC 0 or 1? or negative FISH)
received standard treatment. Costs and effects of no
trastuzumab treatment and a strategy of trastuzumab
treatment of all patients with no predictive testing were
used as reference values. The latter does not represent a
clinically relevant option but was added to demonstrate
the overall magnitude of the benefits achieved with pre-
dictive testing.
False positive and false negative test results lead to
inadequate treatment of the affected patients. Sensitivity
and specificity of IHC and FISH was assessed from pub-
lished literature [30]. Sensitivity and specificity of the
parallel testing strategy were calculated according to the
‘‘believe-the-positive’’ approach, i.e. the combined result
was positive if one test indicated a positive result. Both
tests were regarded as conditional independent (Table 1)
[31].
Disease stages
The simulated population moved through distinct disease
states, namely, disease-free survival, local recurrence,
regional recurrence, metastatic disease and death (Fig. 1).
498 Breast Cancer Res Treat (2010) 124:497–507
123
Local recurrence was defined according to the American
Joint Committee on Cancer (AJCC) as isolated ipsilateral
in-breast cancer recurrence after breast-conserving therapy
of a stage 0–III breast carcinoma [32]. Regional recurrence
included patients with cancer recurrence in the axilla with
or without in-breast recurrence after breast-conserving
therapy of stage 0–II breast carcinoma [33]. Metastatic
disease implied women with progressive metastatic breast
cancer without previous chemotherapy treatment for met-
astatic disease [7].
Clinical data sources
Clinical model inputs, namely, state transition probabilities
for patients with HER-2-positive and HER-2-negative
breast carcinomas (Table 2), were derived from the liter-
ature. We disregarded phase II trials, studies only presented
as conference abstracts, studies with very low sample size,
and studies with insufficient information for being used in
our model. Efficacy results from studies of monoclonal
antibodies targeted against HER-2 other than trastuzumab
were not taken into account. Modelling of disease-free
survival was based on HERA [12]. We assumed that HER-
2-positive individuals with trastuzumab treatment would
have the same transition probabilities as the patients
receiving adjuvant trastuzumab in HERA. The recurrence
rates seen in the HERA comparator group were applied to
our HER-2-positive group without trastuzumab treatment.
In the HER-2-negative situation, transition probabilities
were assumed to be unaffected by trastuzumab treatment
[11].
The future history of patients entering the local and
regional recurrence states was derived from published
retrospective reviews of medical records and was not
dependent on HER-2 status [34, 35]. One-year survival
rates in metastatic breast cancer patients stemmed from two
phase III trials of standard treatment plus trastuzumab
versus best supportive care [7, 36]. It was assumed that
after 5 years, the risk of reappearing metastasis would
decline by 10% annually [37].
Overall mortality rates of the Swiss female population
was taken from published Swiss life tables [38].
Utilities
Utilities were based on a study using the self-administered
EQ-5D questionnaire [39]. Responses were combined with
Table 1 Testing strategies and test characteristics
Test strategy Test Cut-off for HER-2 positivity Sensitivity (±95% CI) Specificity (±95% CI) Ref.
1. All IHC 2? and 3? 0.91 (0.88–0.94) 0.75 (0.72–0.77) [30]
2. All FISH C2.0b 0.98 (0.87–1.0) 0.9 (0.82–0.95) [30]
3. All, parallel testinga IHC 2? and 3? 0.9982 (0.9844–1.0) 0.675 (0.5904–0.7515) [30, 31]
FISHa C2.0b
4. First all IHC 3? 0.905 (0.893–0.933) 0.987 (0.976–0.992) [17]
Second: If IHC2? FISH C2.0b
5. No test, all trastuzumab
6. No test, no trastuzumabc
NB: sensitivity and specificity of the combined tests remain in sequential or parallel testing order the same [58]
a BTP belief the positive. 1 positive test is enough for ? results. Negative result if both test -
b Ratio HER-2/CEP17 signal
c Reference strategy
Fig. 1 Markov model starting with the disease-free health state.
Diagram of model structure, comprising five health states: disease
free, local recurrence, regional recurrence, metastasis (distant recur-
rence) and death
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visual analogue scale-based population preference values.
Utilities per disease stage were: first year after primary
breast cancer, 0.696 (95% confidence interval (CI) 0.634–
0.725); first year after recurrence, 0.779 (CI 0.700–0.849);
second and subsequent years after primary breast cancer/
recurrence, 0.779 (CI 0.745–0.811); metastatic disease
state, 0.685 (CI 0.620–0.735) [39].
Medical resource use
HER-2-positive group
Disease-free status
HER-2-positive patients received trastuzumab after exci-
sion of early stage breast cancer and completion of che-
motherapy. Trastuzumab dosing and planned treatment
duration corresponded to the regimen used in HERA, with
a 8 mg/kg loading dose and 6 mg/kg dose every 3 weeks
during 1 year [12]. We assumed that 15% of the patients
would receive an additional 150 mg vial due to higher
weight ([74 kg). Echocardiography was performed quar-
terly during trastuzumab treatment [12]. All patients
received gynaecological examinations [40]. During
5 years, half of HER-2-positive patients were treated with
aromatase inhibitors (letrozol 2.5 mg/day or anastrozol
1 mg/day) [12].
Local and regional recurrence
Mammography, gynaecological examinations, diagnostic
ultrasound, radiotherapy and surgery including hospitalization,
and aromatase inhibitors (as described above) were used in
these patients [25]. Local recurrence was assumed to be
localized in the thoracic wall (40%) or in the breast (60%) [41].
Metastatic state
Chemotherapy, radiotherapy, diagnostic ultrasound and
palliative surgery including hospitalization, and aromatase
inhibitors (as described above) were used in these patients
[25]. We assumed that 80% of the patients responded to
trastuzumab treatment in the first-line therapy and that half
of these patients were re-treated with trastuzumab for an
additional year when metastases were diagnosed [7].
Untested group
Untested patients all received trastuzumab treatment as
described for the HER-2-positive group. Aromatase
inhibitor was given to 70% of these patients for 5 years
[12, 42, 43].
HER-2-negative group
Patients with no HER-2 overexpression did not receive
trastuzumab but were otherwise treated as described for the
HER-2-positive group. During 5 years, 70% were assumed
to receive hormone therapy [42, 43].
Unit costs
Unit costs (Table 3) for laboratory and diagnostic inter-
ventions were derived from the official Swiss tariff list
[44]. Hospital case-based flat rates and day rates were
Table 2 Annual transition probabilities
HER-2 status Trastuzumab ? Yes ? No - Yes - No Ref.
Disease state Transition to
Disease free Disease free 0.934 0.879 0.975 0.975 [11, 12, 59]
Local recurrence 0.01 0.022 0.004 0.004
Regional recurrence 0.006 0.008 0.004 0.004
Metastatic diseasea 0.05 0.091 0.017 0.017
Local recurrence Disease free 0.878 0.878 0.878 0.878 [35]
Local recurrence 0.028 0.028 0.028 0.028
Metastatic diseasea 0.094 0.094 0.094 0.094
Regional recurrence Disease free 0.895 0.895 0.895 0.895 [34]
Metastatic diseasea 0.105 0.105 0.105 0.105
Metastatic disease Metastatic diseasea 0.78 0.67 0.788 0.788 [7, 36]
Death 0.22 0.33 0.212 0.212
a Transition probabilities only shown for first 5 years. In the subsequent cycles, the model assumed a declined recurrence rate of 10% after each
cycle
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based on Swiss Diagnosis Related Groups (DRGs) [45].
Length of hospital stay was based on data provided by the
Swiss Federal Statistic Office [46]. Drug costs based on
official Swiss pharmacy prices [47]. Costs of diagnostics
and therapeutic interventions in each state were assessed on
this basis. However, as the adjuvant therapy was assumed
to be the same for all patients, costs of initial treatment
(primary breast surgery and adjuvant chemotherapy) were
not included.
Sensitivity analysis
Deterministic sensitivity analysis tested the precision and
robustness of the results. Parameters with a direct impact
on incremental costs were varied by ±30% (price of
trastuzumab, price of predictive tests, costs of local and
regional recurrence and metastatic disease). Medical
resource use was not varied separately as it was assumed
that any related uncertainty would be covered by the var-
iation of unit costs. The discount rate was set to 0 and 6%.
In addition, variables subject to statistical uncertainty
(sensitivity and specificity of IHC and FISH, metastatic,
local and regional recurrence rates, utilities) were varied
within their 95% confidence intervals (CIs) [48]. The
prevalence of a normal (negative) HER-2 expression pat-
tern was varied between 75 and 85%.
Probabilistic sensitivity analysis
Uncertainty around the base case results was additionally
assessed by probabilistic sensitivity analysis (PSA), using
10,000 sets of parameter values randomly sampled from
beta distributions reflecting the ranges of variation used in
deterministic sensitivity analysis [49]. Parameters covered
included HER-2 prevalence, utilities, transition probabili-
ties, and test sensitivity and specificity. Unit costs were not
subject to uncertainty and therefore not included in the
PSA [44].
Model implementation
The Markov model was implemented in TreeAge Pro
2009 (TreeAge Software Inc, Williamstown, MA, USA).
Table 3 Cost per type of resource use (per first year in € per patient)
Type of resource Duration/amount Unit cost (€) Ref.
Hormonal therapy 1 year 2,233 [44, 47]
Trastuzumab price (Herceptin, Roche, Switzerland) 1 vial per 150 mg 860 [47]
1 vial per 440 mg 2,341
Trastuzumab treatment (Incl. Infusion and 49 echocardiography) 1 year 42,588 [44, 47]
IHC test 1 test 53 [44]
FISH testa 2 test probes 686 [44]
Gynaecological examinationb 1 142 [44]
Mammography 1 107 [44]
Sonography 1 year 100 [44]
Surgery 1 year 1,275c [44]
2,778d
Material 1 year 167 [44]
Anaesthesia 1 year 540 [44]
Radiotherapy 1 year 4,688e [44]
8,467f
Hospitalization 7.6 days 2,281g [60]
a Based on the resource use in Swiss laboratories
b According to the Swiss Consortium for Gynaecological Oncology and Obstetrics (AGO) [40]: four examinations per year in the years 1–3, two
examinations in the years 4–5, one examination in the years 5–10 and biennial examinations thereafter
c Local recurrence in the breast
d Thoracic local recurrence and regional recurrence
e For thoracic local recurrence
f For regional recurrence
g Average duration of stay of C500 to C509 (ICD10 classification) during 2005 in Switzerland
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Results
Base case analysis
Effect
Differences in effectiveness between the strategies
involving trastuzumab treatment arose from imperfect
sensitivity and specificity of the testing strategies
(Table 1). Some HER-2-positive patients had false nega-
tive test results and hence did not receive trastuzumab,
which lead to a loss of QALYs. Therefore, the no testing
strategy (where all patients received trastuzumab) accrued
most QALYs (12.751 QALYs per patient). The testing
strategies accrued between 12.741 and 12.750 QALYs. At
the lower end, the no trastuzumab strategy resulted in
12.254 QALYs (Table 4).
Costs
Trastuzumab substantially increased costs in both the
testing and non-testing strategies, compared to no trast-
uzumab treatment. However, the increase was distinctly
lower in the testing strategies. Here, trastuzumab costs
were strongly reduced as therapy was targeted to those
patients who profited most (Table 4).
Per-patient total lifetime costs in the predictive testing
strategies ranged from €38,153 (FISH confirmation of
IHC2?) to €41,830 (parallel IHC and FISH). FISH con-
firmation of IHC2? saved €62 in comparison to FISH
alone. If FISH alone was used, per-patient savings
compared to IHC alone and parallel IHC and FISH would
be €1,736 and €3,615, respectively.
Incremental cost–effectiveness
The reference (no trastuzumab) strategy was least costly
and least effective (€32,258 and 12.254 QALYs per
patient) (Table 4). FISH alone testing was associated with
a per-patient cost of €38,215 and resulted in 12.741 QA-
LYs, corresponding to an ICER of €12,245/QALY when
compared with the no trastuzumab strategy. This was the
most favourable ICER observed. FISH alone testing dom-
inated IHC alone and FISH confirmation of IHC2?. In the
latter comparison, FISH alone was in a situation of
extended dominance [50], e.g.it was slightly more expen-
sive but showed a better incremental cost–effectiveness
ratio than the comparator. Superior characteristics of the
FISH test lead to a gain in clinical effectiveness and hence,
clinical savings that over-compensated or near-compen-
sated much higher test costs. The ICER of parallel IHC and
FISH was €400,154/QALY compared to FISH alone.
ICERs for the non-testing approach were prohibitively
high. Figure 2 summarizes cost–effectiveness results.
Current Swiss data show an annual average of 5,091
incident breast cancer cases between 2001 and 2005 [51].
On this basis, FISH confirmation of IHC2? versus FISH
alone would lead to cost savings of €315,642, and lose 245
QALYs, per year. FISH alone compared to IHC alone
would save €8,837,976, and gain 177 QALYs, per year.
FISH alone compared to parallel IHC and FISH would lead
to savings of €18,403,965 and a loss of 46 QALYs.
Table 4 Base case cost–effectiveness analysis (CEA) of different testing strategies (reference: no trastuzumab)
Test strategy Lifetime cost
per person
Lifetime
efficacy
C/E Incremental
costsa
Incremental
efficacyb
ICER
Unit € QALY €/QALY € QALY €/QALY
No trastuzumabc 32,258 12.254 2,632 – – –
IHC first (FISH only for IHC2?) 38,153 12.693 3,006 (5,895)d (0.4384)d Dominatedd
FISH alone 38,215 12.741 2,999 5,957e 0.4865e 12,245e
IHC alone 39,951 12.706 3,144 (1,736)f (-0.0348)f Dominatedf
Parallel IHC and FISH 41,830 12.750 3,281 3,615g 0.0090g 400,154g
NO test 53,860 12.751 4,224 12,030h 0.0009h 13,456,577h
a Relative to the strategy with the next lower cost
b Relative to the strategy with the next lower efficacy
c Reference strategy
d Compared to the reference strategy (no trastuzumab)
e Extendedly dominated by FISH alone (extended dominance: is applied to remove from consideration strategies whose cost–effectiveness is
inferior in comparison with at least one more expensive strategy)
f Dominated by FISH alone (simple dominance: a strategy is dominated by another if the former both costs more and is less effective)
g Compared to FISH alone
h Compared to parallel IHC and FISH
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Sensitivity analysis
In deterministic sensitivity analysis, varying the price of
trastuzumab and the discount rate had substantial influence
on the results. Variation of other unit costs (apart from
trastuzumab), cancer recurrence rates, test sensitivity or
specificity, utilities or the HER-2 overexpression pattern
did not influence the ranking of strategies. The ICERs for
the non-dominated strategies were essentially sustained in
all situations analyzed (Fig. 3, Table 5). The rank order of
the testing strategies was also robust (Table 5). However, if
the specificity of FISH alone was set a low value of 0.82
(while specificity was left unchanged for the other strate-
gies), FISH confirmation of IHC2? would become the
preferred strategy due to its much higher specificity value.
None of the other analyses performed affected the prefer-
ability of FISH alone (Fig. 3).
At a willingness to pay per QALY gained of €13,333,
the FISH testing approach became dominant until at
€380,000, parallel FISH and IHC became the preferred
strategy (Fig. 4a). Further PSA results are shown in
Fig. 4b.
Discussion
We modelled the cost–effectiveness of different predic-
tive HER-2 testing strategies, prior to trastuzumab
treatment of adjuvant breast cancer patients, from a
Swiss health system perspective. FISH alone testing with
subsequent trastuzumab treatment of HER-2-positive
patients was identified as the most cost–effective
approach, with an ICER of €12,245 per QALY gained
compared to no trastuzumab use. It dominated other
testing strategies or these showed unfavourable cost–
effectiveness ratios. Sensitivity analysis showed these
results to be robust over a wide range of assumptions. As
a limitation, we did not take into account a possible
Fig. 2 Cost–effectiveness analysis. Graphical representation of
incremental cost–effectiveness results. IHC alone (2–3?) is domi-
nated by FISH alone, i.e. less effective and more expensive. IHC first
(FISH only 2?) is extendedly dominated by FISH alone, i.e. less
expensive but also less cost–effective. For the remaining strategies,
the slope of the dotted line represents incremental cost–effectiveness
Fig. 3 Plot of the deterministic sensitivity analyses for parameter
uncertainty with regard to the ICER of FISH testing compared with
no trastuzumab. Larger bars indicate stronger sensitivity of the base
case ICER of FISH testing versus the reference strategy to uncertainty
around the respective parameters. DF disease free, FISH fluorescence
in situ hybridisation, ICER incremental cost–effectiveness ratio, IHC
immunhistochemistry, LLR local/regional recurrence, LR local recur-
rence, MD metastatic disease, MR metastatic recurrence, NT no
trastuzumab, P probability, RR regional recurrence, Sens sensitivity,
Spec specificity, T trastuzumab. *In this sensitivity analysis, FISH
confirmation of IHC2? becomes the preferred strategy with an ICER
of €13,448 compared to reference strategy
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influence of false positive and false negative test results
on the event risks reported in HERA and in the other
trials used for deriving transition probabilities in this
modelling study. This would have required complex
correction procedures and tentative assessments indicated
a minor impact.
Table 5 One-way sensitivity analysis of incremental costs (€) per QALY gained (ICER) without dominated strategies
Testing strategy FISH alone vs.
no trastuzumab
Parallel testingc
vs. FISH alone
NO TEST vs.
parallel testing
Baseline 12,245 400,154 13,456,577
Price trastuzumab ?30% 15,982 531,788 17,377,558
Price trastuzumab -30% 8,507 268,544 9,549,342
Price all predictive tests ?30% 12,398 398,547 13,396,396
Price all predictive tests -30% 12,091 401,785 13,530,503
Cost of FISH test probe -50% 11,892 400,129 13,655,867
Cost metastatic basis treatment ?30%a,b 11,806 399,727 13,463,011
Cost metastatic basis treatment -30%a,b 12,683 400,605 13,463,889
Cost local recurrence ?30%a 12,181 400,102 13,463,386
Cost local recurrence -30%a 12,308 400,230 13,463,514
Cost regional recurrence ?30%a 12,243 400,164 13,463,448
Cost regional recurrence -30%a 12,246 400,168 13,463,451
Discount rate 6% 18,721 636,009 21,215,854
Discount rate 0% 7,644 230,451 7,818,473
a Without consideration of hormone therapy
b Price for trastuzumab not included
c Parallel both tests (BTP): either IHC (2–3?) or FISH? test result needed for HER-2? status
Fig. 4 Results from the
probabilistic sensitivity analysis
(PSA). a Acceptability frontier.
The cost–effectiveness
acceptability frontier shows the
PSA-based probability of
testing strategies of being cost–
effective. For different
willingness to pay thresholds,
different strategies are optimal.
For each threshold, only the
probability for the optimal
strategy is shown.
b Incremental cost (€)–
effectiveness scatter plot of all
testing options. The cost–
effectiveness scatter plot uses
the cost–effectiveness plane to
plot a test cost and effectiveness
pair for each recalculation of
the model (10,000 runs)
504 Breast Cancer Res Treat (2010) 124:497–507
123
In routine practice, many local laboratories only use IHC.
Central laboratories often use FISH to confirm IHC2?, as
was the case in the HERA study [12]. Both of these strategies
were dominated by the FISH alone strategy in our model.
The inferiority (extended domination) of FISH confirmation
of IHC2? was due to this strategy, clinical characteristics,
although it was cheaper than FISH alone.
In Switzerland, many central laboratories have started to
use primary FISH assays. However, IHC may be added in
unclear cases. The implications were difficult to assess as
no sensitivity or specificity data for FISH equivocal sam-
ples (HER-2/CEP17 ratio signal between 1.8 and 2.2) were
available from the literature. A tentative assessment
assuming a hypothetical sensitivity of 0.892 (CI 0.766–
0.94 [30, 31]) indicated a quality-adjusted survival of
12.470 QALYs and hence no further gain in clinical
effectiveness.
In a recent cost–effectiveness analysis in the metastatic
setting, conducted by Elkin et al., trastuzumab treatment
without predictive testing was dominated by a testing
strategy not covered here, namely, the confirmation of
IHC2? or 3? with FISH [26]. Only patients with a positive
result in both tests received trastuzumab, i.e. considerably
fewer than in our combined IHC and FISH strategy. It may
indeed make sense to use stricter criteria for trastuzumab
treatment in the metastatic than in the adjuvant setting.
However, the strategy of FISH confirmation of IHC 2–3?
was also assessed for non-metastatic patients. In a meta-
analysis by Dendukuri et al. [17], focusing on invasive
breast cancer patients, and in a Swedish cost–effectiveness
analysis studying adjuvant breast cancer patients [27], it
was again identified as the strategy with the best ICER. Of
note, the former study only took into account diagnostic
costs; it disregarded trastuzumab costs [17]. The latter
estimated IHC scores from FISH results, based on Elkin
et al. [26], and thus made an implicit assumption of
dependency of IHC and FISH. In a separate implementa-
tion of the model, we estimated the lifetime costs and
effects of the strategy defined by Elkin et al. in the adjuvant
setting. After reducing sensitivity (0.892, CI 0.766–0.94)
and increasing specificity (0.975, CI 0.950–0.989) [30, 31],
costs summed up to €36,706 in combination with 12.697
QALYs gained. Indeed, this would imply a favourable
ICER. However, due to a low practical relevance in the
adjuvant setting, and presumable lack of acceptability in a
resource-rich setting, we did not incorporate this strategy
into the main analysis.
Recent evidence suggests that HER-2 expression in
primary and advanced tumour tissue may be discordant by
5–10% [52–57]. HER-2 status may therefore be re-assessed
before starting trastuzumab treatment in metastatic breast
cancer patients experiencing disease progression. However,
our model focuses on adjuvant therapy and we did not
attempt to assess the economic implications of this
approach, as currently, this is not routine practice.
A recent review favours FISH over IHC for accuracy,
reproducibility and precision reasons [16]. According to
this source, 15–48% of equivocal IHC2? breast cancers
show HER-2 gene amplification. In addition, 2–8% of IHC
0/1? breast cancers are FISH amplified. Around 5–22% of
IHC 3? breast cancers have no gene amplification (false
negativity) [16]. In addition, a positive FISH status points
towards a stronger responsiveness to trastuzumab. The use
of FISH testing diminishes the number of patients eligible
for trastuzumab therapy due to both superior sensitivity and
specificity compared to IHC [16]. These findings favour
primary FISH testing and are consistent with our health
economic result.
Conclusion
Clinically useful predictive tests with reasonable sensitivity
and specificity to predict drug-response are one cornerstone
in achieving a cost–effective implementation of new
treatment strategies in oncology. Currently, many novel
predictive assays (e.g. k-ras testing in colorectal cancer,
EGFR mutation analysis in lung cancer) are being intro-
duced. Results from carefully conducted health economic
analyses should inform future guidelines on the use of such
tests. In the adjuvant breast cancer setting, primary FISH
testing with subsequent trastuzumab treatment of HER-2-
positive patients is a cost–effective and preferable
approach.
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